Last Updated: 09 Nov 2024
Executive Summary
Harrow Health Inc. (HROW) is an ophthalmology-focused healthcare company with a market capitalization of $1.77 billion. The company has recently reported a -0.64% decline in quarterly earnings growth year over year, but a 0.462% increase in quarterly revenue growth year over year. Analysts have a strong buy rating on the stock, with a target price of $59.45. The current stock price is $52.51, indicating a potential upside of 13.4%.
Company Overview
Harrow Health Inc. is headquartered in San Diego, California. It is an ophthalmology-focused healthcare company that develops, manufactures, and markets ophthalmic pharmaceuticals and devices. The company's products include treatments for dry eye disease, glaucoma, and other eye conditions.
Fundamental Analysis
Revenue: $154.1 million TTM
Gross Profit: $63.2 million TTM
EBITDA: $3.2 million TTM
Net Income: -$33.6 million TTM
EPS: -$0.95 TTM
Book Value: $1.65 per share
Trailing PE: N/A
Forward PE: N/A
Price-to-Sales Ratio: 11.49
Price-to-Book Ratio: 29.24
EV/Revenue: 11.89
EV/EBITDA: 743.79
Beta: 0.763
Technical Analysis
52-Week High: $59.23
52-Week Low: $7.60
50-Day Moving Average: $46.68
200-Day Moving Average: $24.79
Relative Strength Index (RSI): 55.38
Short Term Outlook
Technically, HROW is in a bullish trend, trading above its 50-day and 200-day moving averages. The RSI is also in bullish territory, indicating that the stock is not overbought. The stock price is currently consolidating after a recent rally, and a breakout above the $55 level could lead to further gains.
Long Term Outlook
The long-term outlook for HROW is positive. The company is a leader in the ophthalmology market, and it has a strong pipeline of new products. The company is also expected to benefit from the aging population, which is driving demand for ophthalmic treatments.
Analyst Recommendations
Analysts have a strong buy rating on HROW, with a target price of $59.45. The consensus recommendation is to buy the stock.
